Sofia Heigis presents at Redeye Commercialization in Life Science event on March 20
Oncopeptides’ CEO Sofia Heigis will present at Redeye’s event: Commercialization in Life Science on March 20, 2024.
Oncopeptides’ CEO Sofia Heigis will present at Redeye’s event: Commercialization in Life Science on March 20, 2024.
Oncopeptides AB recently announced that the Board of Directors has decided to carry out a fully guaranteed new share issue of approximately SEK 300 million with preferential rights for the company’s existing ordinary shareholders. Q&A updated March 15.
See Oncopeptalks, Q&A for investors and link to the recorded webcast
February 23, 2024
Oncopeptides AB (publ) today announces that the U.S. Food and Drug Administration (FDA) has made a decision regarding the withdrawal of Pepaxto, which Oncopeptides had appealed.
Read moreFebruary 23, 2024
Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that the Spanish Drug Pricing Authority (CIPM) has published a positive recommendation for the pricing of melflufen, branded in Europe as Pepaxti.
Read moreFebruary 15, 2024
Oncopeptides AB today announces that it will receive an extension of a key patent ensuring market exclusivity for melflufen, marketed in Europe as Pepaxti, in Europe until 2037, an extension of five years.
Read moreMarch 1, 2024
Oncopeptides today announces that a new article analyzing scientific data on melflufen, marketed in Europe as Pepaxti, was recently published in the peer-reviewed medical journal Clinical Lymphoma, Myeloma and Leukemia.
Read moreFebruary 29, 2024
Oncopeptides today announces that a new article analyzing health-related quality of life in patients treated with melflufen, marketed in Europe as Pepaxti, has been published in Haematologica.
Read moreFebruary 7, 2024
Oncopeptides recently received a favorable opinion from EMA to revert back to the originally approved indication for Pepaxti. This means that the previously communicated decision to opt out of the process to extend the indication has now been fully realized.
Read moreMarch 18, 2024
Oncopeptides’ CEO Sofia Heigis will present at Redeye’s event: Commercialization in Life Science on March 20, 2024.
Read moreMarch 13, 2024
Listen to why Oncopeptides is carrying out a new share issue, where the money will go, what a rights issue really is and what you as a current or potential shareholder should think about.
Read moreMarch 6, 2024
Sofia Heigis presented Oncopeptides on Tuesday at Stora Aktiedagarna in Stockholm. During her presentation, followed by a question and answer session, Sofia gave an update on the company, focusing on the changing treatment landscape for melflufen and commercialization in Europe. See the recorded presentation (in Swedish).
Read morePress release - March 13, 2024
Released February 27, 2024
CEO Sofia Heigis
David Augustsson
Director Corporate Affairs
david.augustsson@oncopeptides.com
+46 762 29 38 68
Oncopeptides AB Q1 interim report 2024 will be published May 30, 2024
2024-04-15
Meeting
2024-04-22
Report
2024-04-29 - 2024-05-29
Other
”Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”
We are a science driven, entrepreneurial company, committed to bringing innovation to patients with an unmet medical need, and improving their lives.